Clinical Trial Update: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 open-label study updating long-term safety and efficacy of adalimumab in ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED | Results posted: 2017-12-19